Atopic Dermatitis

A dermatology expert discusses taking a nuanced approach to interpreting the boxed warnings for JAK inhibitor for atopic dermatitis (AD) treatment.

Andrew Blauvelt, MD, provides an overview of the significance of JAK/Stat pathway inhibition in targeting the pathophysiology of atopic dermatology (AD).

Andrew Blauvelt, MD, provides an overview of different treatment options that are available for patients with moderate to severe atopic dermatitis (AD).

Christopher G. Bunick, MD, PhD, shares their clinical approach for switching therapies for atopic dermatitis (AD) treatment.

A dermatology expert provides an overview of the results of the meta-analysis data from the RAD 2023 atopic dermatitis (AD) trial.

Christopher G. Bunick, MD, PhD, discusses underutilized efficacy outcomes in atopic dermatitis (AD) clinical trials.

A dermatology expert discusses how numerical rating scale (NRS) is used in atopic dermatitis (AD) clinical trials.

A dermatology expert discusses how the standard of care EASI scores have been improving with newer atopic dermatitis (AD) therapies.

Christopher G. Bunick, MD, PhD, provides an overview of clinical trial outcomes in atopic dermatitis (AD).

Christopher G. Bunick, MD, PhD, discusses what can be done to improve the standard of care for atopic dermatitis (AD).

Drs Keegan and Cameron discuss patient-specific considerations for selecting optimal atopic dermatitis treatment strategies.

Off-label use of JAK inhibitors can prove beneficial in the treatment of several dermatologic conditions.

Experts in dermatology share practice pearls and takeaways for treatment of atopic dermatitis.

Expert dermatologists discuss treatment discontinuation as a barrier to achieving desired outcomes in atopic dermatitis.

Aaron S. Farberg, MD, comments on use of different treatments for atopic dermatitis when a patient does not respond to treatment.

Expert dermatologists review the positive impact dupilumab has on quality of life for a patient with atopic dermatitis.

Experts in dermatology discuss efficacy and patient-reported outcomes of topical and systemic JAK inhibitors and dosing guidelines in atopic dermatitis.

In this interview, Hebert discussed recent positive topline results from the ADORING 1 trial on tapinarof cream for atopic dermatitis patients aged 2 years and older.

Matthew Zirwas, MD, provides insight into the ideal candidates for use of ruxolitinib to treat atopic dermatitis, focusing on patients with sensitive skin.

Expert dermatologists review the safety data of topical ruxolitinib in the treatment of atopic dermatitis.

Alexandra Golant, MD, highlights the positive clinical data of ruxolitinib, a topical JAK inhibitor used for the treatment of atopic dermatitis.

Peter A. Lio, MD, provides an overview of emerging JAK inhibitors in the treatment of atopic dermatitis.

In this interview, de Benedetto discusses the major takeaways from her RAD 2023 conference presentation titled ‘New discoveries in the science of atopic dermatitis.’

In this interview segment, Chovatiya touched upon the late-breaking data he had presented at RAD 2023 conference on tapinarof cream 1% for younger eczema patients.

In his RAD 2023 conference presentation, Chovatiya discussed data on recent therapies for eczema such as upadacitinib, ruxolitinib, tralokinumab, and dupilumab.